Back

Comparing dual antiplatelet therapy strategies post-acute coronary syndrome: network meta-analysis

27 August 2022 (17:15 - 18:00)
Organised by:
Congress Presentation Part of: Short and long-term antiplatelet therapy in clinical practice Antiplatelet Drugs ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Ricky Turgeon

University of British Columbia, Vancouver (Canada)

7 More presentations in this session

Presentation thumbnail
Short dual antiplatelet therapy duration in high bleeding risk patients undergoing PCI for non-ST-elevation acute coronary syndrome
Doctor D. Cao (Milan, IT)
Abstract Slides
Presentation thumbnail
CYP2C19 loss-of-function alleles and the use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel - a real-world study
Mr M. Ritvos (Helsinki, FI)
Abstract Slides
Presentation thumbnail
Bentracimab demonstrates reversal of antiplatelet effects of ticagrelor: impact of hematocrit and generic versions of ticagrelor in vitro
Professor B. Curry (Memphis, US)
Abstract Slides
Presentation thumbnail
Intravenous antiplatelet therapy with cangrelor vs. tirofiban in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention
Doctor M. Centore (Salerno, IT)
Abstract Slides
Presentation thumbnail
Thirty-days versus standard duration of dual antiplatelet treatment after percutaneous coronary interventions: a systematic review and meta-analysis
Doctor A. Apostolos (London, GB)
Abstract Slides

Access the full session

Session thumbnail
Short and long-term antiplatelet therapy in clinical practice

The Event

Event poster

ESC Congress 2022

27 August 2022 17:15 CET
You may be interested in
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes
thumbnail
Congress Session
State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources